R Lahtinen

1.6k total citations
31 papers, 1.1k citations indexed

About

R Lahtinen is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, R Lahtinen has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 12 papers in Genetics and 10 papers in Oncology. Recurrent topics in R Lahtinen's work include Acute Myeloid Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). R Lahtinen is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Multiple Myeloma Research and Treatments (8 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers). R Lahtinen collaborates with scholars based in Finland, Sweden and Hungary. R Lahtinen's co-authors include Markku Laakso, Pekka Virkkunen, Inkeri Elomaa, I. P. Palva, Albert de la Chapelle, Tapani Ruutu, Allan Rajamäki, Kari Pulkki, Anri Tienhaara and T. Nousiainen and has published in prestigious journals such as The Lancet, Blood and European Journal of Cancer.

In The Last Decade

R Lahtinen

30 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R Lahtinen Finland 17 669 530 247 164 145 31 1.1k
Nora Viniou Greece 15 546 0.8× 489 0.9× 339 1.4× 321 2.0× 76 0.5× 43 1.1k
Emanuela Englaro Italy 10 556 0.8× 510 1.0× 297 1.2× 83 0.5× 180 1.2× 15 1.2k
Marta Krejčí Czechia 17 832 1.2× 574 1.1× 497 2.0× 190 1.2× 60 0.4× 155 1.3k
P. Berthaud France 14 465 0.7× 409 0.8× 248 1.0× 311 1.9× 498 3.4× 42 1.3k
Tomáš Skácel Switzerland 16 343 0.5× 819 1.5× 281 1.1× 55 0.3× 249 1.7× 33 1.0k
Delia Cangini Italy 15 1.4k 2.1× 960 1.8× 922 3.7× 203 1.2× 71 0.5× 32 1.7k
Parameswaran Venugopal United States 21 1.1k 1.6× 412 0.8× 684 2.8× 482 2.9× 72 0.5× 130 1.9k
Susan McKenzie United States 14 766 1.1× 342 0.6× 367 1.5× 247 1.5× 54 0.4× 19 1.2k
Thomas Fietz Germany 16 303 0.5× 413 0.8× 88 0.4× 192 1.2× 154 1.1× 40 872
P J Dady New Zealand 14 241 0.4× 359 0.7× 124 0.5× 51 0.3× 192 1.3× 25 815

Countries citing papers authored by R Lahtinen

Since Specialization
Citations

This map shows the geographic impact of R Lahtinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Lahtinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Lahtinen more than expected).

Fields of papers citing papers by R Lahtinen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Lahtinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Lahtinen. The network helps show where R Lahtinen may publish in the future.

Co-authorship network of co-authors of R Lahtinen

This figure shows the co-authorship network connecting the top 25 collaborators of R Lahtinen. A scholar is included among the top collaborators of R Lahtinen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Lahtinen. R Lahtinen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pulkki, Kari, Tarja‐Terttu Pelliniemi, Allan Rajamäki, et al.. (1996). Soluble interleukin‐6 receptor as a prognostic factor in multiple myeloma. British Journal of Haematology. 92(2). 370–374. 71 indexed citations
2.
Elomaa, Inkeri, Leila Risteli, Markku Laakso, et al.. (1996). Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. European Journal of Cancer. 32(7). 1166–1170. 25 indexed citations
3.
Jantunen, Esa, R Lahtinen, & Markku Laakso. (1995). USe of Clodronate in Multiple Myeloma. Leukemia & lymphoma. 19(3-4). 207–211. 8 indexed citations
4.
Jantunen, Esa, et al.. (1994). Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: A case report with review of the literature. American Journal of Hematology. 46(3). 218–224. 39 indexed citations
5.
Laakso, Saila, R Lahtinen, Pekka Virkkunen, & Inkeri Elomaa. (1994). Subgroup and cost‐benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. British Journal of Haematology. 87(4). 725–729. 63 indexed citations
6.
Jantunen, Esa, Esa Soppi, Heikki Neittaanmäki, & R Lahtinen. (1993). Essential cryofibrinogenaemia, leukocytoclastic vasculitis and chronic purpura. Journal of Internal Medicine. 234(3). 331–333. 21 indexed citations
7.
Lahtinen, R, Markku Laakso, I. P. Palva, Inkeri Elomaa, & Pekka Virkkunen. (1992). Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. The Lancet. 340(8827). 1049–1052. 300 indexed citations
8.
Hämäläinen, Esa, et al.. (1992). Comparison of poly‐ and monoclonal antibodies for determination of B‐cell clonal excess in an routine clinical laboratory. European Journal Of Haematology. 48(1). 49–55. 5 indexed citations
9.
Palva, I. P., A. Almqvist, Erkki Elonen, et al.. (1991). Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia. European Journal Of Haematology. 47(3). 229–233. 23 indexed citations
10.
Lahtinen, R, Jyrki T. Kuikka, T. Nousiainen, Matti Uusitupa, & Esko Länsimies. (1991). Cardiotoxicity of epirubicin and doxorubicin: A double‐blind randomized study. European Journal Of Haematology. 46(5). 301–305. 53 indexed citations
11.
Wranne, Bengt, L. Jorfeldt, Gösta Berlin, et al.. (1991). Effect of hemodilution on maximal oxygen consumption, blood lactate response to exercise and cerebral blood flow in subjects with a high‐affinity hemoglobin. European Journal Of Haematology. 47(4). 268–276. 2 indexed citations
12.
Soppi, Esa, T. Nousiainen, Anders Seppä, & R Lahtinen. (1989). Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. British Journal of Haematology. 73(1). 43–47. 56 indexed citations
13.
Kere, Juha, Tapani Ruutu, R Lahtinen, & Albert de la Chapelle. (1987). Molecular characterization of chromosome 7 long arm deletions in myeloid disorders. Blood. 70(5). 1349–1353. 44 indexed citations
14.
Chapelle, Albert de la & R Lahtinen. (1987). Monosomy 7 predisposes to diabetes insipidus in leukaemia and myelodysplastic syndrome. European Journal Of Haematology. 39(5). 404–411. 32 indexed citations
15.
Länsimies, Esko, et al.. (1985). EXERCISE CAPACITY IN SUBJECTS WITH HIGH OXYGEN AFFINITY. Clinical Physiology. 5(s3). 69–73. 3 indexed citations
16.
Puolakka, Kari, Timo Korhonen, & R Lahtinen. (1984). Diabetes insipidus in preleukaemic phase of acute myeloid leukaemia in 2 patients with empty della turcica: A report of 2 cases. Scandinavian Journal of Haematology. 32(4). 364–366. 15 indexed citations
17.
Lahtinen, R, et al.. (1983). Increased bone marrow blood flow in polycythemia vera. European Journal of Nuclear Medicine and Molecular Imaging. 8(1). 19–22. 14 indexed citations
18.
Lahtinen, R, Tapani Lahtinen, & Timo Romppanen. (1982). Bone and bone-marrow blood flow in chronic granulocytic leukemia and primary myelofibrosis.. PubMed. 23(3). 218–24. 21 indexed citations
19.
Teerenhovi, L., G.H. Borgström, Tapani Ruutu, et al.. (1981). The 5q— Chromosome in Preleukaemia and Acute Leukaemia. Scandinavian Journal of Haematology. 27(2). 119–129. 32 indexed citations
20.
Lahtinen, Tapani, et al.. (1981). The partition coefficients of 133Xe between human blood and bone. Physics in Medicine and Biology. 26(1). 125–132. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nora Viniou Breakdown of academic impact, for papers by Emanuela Englaro Breakdown of academic impact, for papers by Marta Krejčí Breakdown of academic impact, for papers by P. Berthaud Breakdown of academic impact, for papers by Tomáš Skácel Breakdown of academic impact, for papers by Delia Cangini Breakdown of academic impact, for papers by Parameswaran Venugopal Breakdown of academic impact, for papers by Susan McKenzie Breakdown of academic impact, for papers by Thomas Fietz Breakdown of academic impact, for papers by P J Dady
Rankless by CCL
2026